RIGL Valuation

Rigel Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

38.850

-0.46(-1.170%)1D

Overview
Forecast
Valuation
Earnings

RIGL Relative Valuation

RIGL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RIGL is overvalued; if below, it's undervalued.

Historical Valuation

Rigel Pharmaceuticals Inc (RIGL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.87 is considered Undervalued compared with the five-year average of -19.49. The fair price of Rigel Pharmaceuticals Inc (RIGL) is between 194.96 to 233.29 according to relative valuation methord. Compared to the current price of 38.85 USD , Rigel Pharmaceuticals Inc is Undervalued By 80.07%.

Relative Value

Fair Zone

194.96-233.29

Current Price：38.85

80.07%

Undervalued

15.74

Trailing

Forward

5.51

EV/EBITDA

Rigel Pharmaceuticals Inc. (RIGL) has a current EV/EBITDA of 5.51. The 5-year average EV/EBITDA is -9.99. The thresholds are as follows: Strongly Undervalued below -56.36, Undervalued between -56.36 and -33.17, Fairly Valued between 13.20 and -33.17, Overvalued between 13.20 and 36.38, and Strongly Overvalued above 36.38. The current Forward EV/EBITDA of 5.51 falls within the Historic Trend Line -Fairly Valued range.

11.69

EV/EBIT

Rigel Pharmaceuticals Inc. (RIGL) has a current EV/EBIT of 11.69. The 5-year average EV/EBIT is 4.51. The thresholds are as follows: Strongly Undervalued below -326.50, Undervalued between -326.50 and -161.00, Fairly Valued between 170.01 and -161.00, Overvalued between 170.01 and 335.52, and Strongly Overvalued above 335.52. The current Forward EV/EBIT of 11.69 falls within the Historic Trend Line -Fairly Valued range.

2.87

Rigel Pharmaceuticals Inc. (RIGL) has a current PS of 2.87. The 5-year average PS is 2.84. The thresholds are as follows: Strongly Undervalued below -0.70, Undervalued between -0.70 and 1.07, Fairly Valued between 4.61 and 1.07, Overvalued between 4.61 and 6.38, and Strongly Overvalued above 6.38. The current Forward PS of 2.87 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Rigel Pharmaceuticals Inc. (RIGL) has a current P/OCF of 0.00. The 5-year average P/OCF is 6.76. The thresholds are as follows: Strongly Undervalued below -63.31, Undervalued between -63.31 and -28.28, Fairly Valued between 41.79 and -28.28, Overvalued between 41.79 and 76.83, and Strongly Overvalued above 76.83. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Rigel Pharmaceuticals Inc. (RIGL) has a current P/FCF of 0.00. The 5-year average P/FCF is 1.51. The thresholds are as follows: Strongly Undervalued below -20.66, Undervalued between -20.66 and -9.57, Fairly Valued between 12.60 and -9.57, Overvalued between 12.60 and 23.69, and Strongly Overvalued above 23.69. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Rigel Pharmaceuticals Inc (RIGL) has a current Price-to-Book (P/B) ratio of 8.51. Compared to its 3-year average P/B ratio of -3.39 , the current P/B ratio is approximately -350.72% higher. Relative to its 5-year average P/B ratio of 2.01, the current P/B ratio is about 323.88% higher. Rigel Pharmaceuticals Inc (RIGL) has a Forward Free Cash Flow (FCF) yield of approximately 9.44%. Compared to its 3-year average FCF yield of -10.56%, the current FCF yield is approximately -189.40% lower. Relative to its 5-year average FCF yield of -8.83% , the current FCF yield is about -206.89% lower.

8.51

P/B

Median3y

-3.39

Median5y

2.01

9.44

FCF Yield

Median3y

-10.56

Median5y

-8.83

Competitors Valuation Multiple

The average P/S ratio for RIGL's competitors is 58.93, providing a benchmark for relative valuation. Rigel Pharmaceuticals Inc Corp (RIGL) exhibits a P/S ratio of 2.87, which is -95.13% above the industry average. Given its robust revenue growth of 176.01%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

RIGL.O

Rigel Pharmaceuticals Inc

Theravance Biopharma Inc

Gyre Therapeutics Inc

Arbutus Biopharma Corp

Mind Medicine (MindMed) Inc

Loss

675.66M

KALV.O

Kalvista Pharmaceuticals Inc

19.60

677.57M

Performance Decomposition

Market capitalization of RIGL increased by 140.11% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 0.32 to 7.15.

The secondary factor is the Revenue Growth, contributed 176.01%to the performance.

Overall, the performance of RIGL in the past 1 year is driven by P/E Change. Which is more unsustainable.

176.01%

36.84M → 101.69M

Revenue Growth

-2193.93%

-2.80 → 58.63

Margin Expansion

2158.03%

0.32 → 7.15

P/E Change

140.11%